Multicenter Study Evaluating the Safety of ProellexÂ® in Premenopausal Women With Uterine Fibroids
The safety of Proellex 25 and 50 mg administered once daily for three treatment cycles (four months each) will be evaluated.
Uterine Fibroids
DRUG: Proellex 25 mg|DRUG: Proellex 50 mg
To Assess the Safety of Proellex Administered Once Daily for Three Treatment Cycles (4 Months Each Cycle), 12 months
Subjects will be randomized to either Proellex dose, 25 mg or 50 mg, in a 1:1 ratio. Subjects will receive drug for a four (4) month cycle of therapy three (3) times, each treatment cycle being separated by an off-drug interval until menstruation occurs. During the treatment periods, all subjects will be assessed monthly. Subjects will undergo an additional follow-up for 3 months following their last treatment visit.